Compare OHI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OHI | EXEL |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 17.8B |
| IPO Year | 2001 | 2000 |
| Metric | OHI | EXEL |
|---|---|---|
| Price | $47.17 | $69.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 17 |
| Target Price | $51.68 | ★ $61.57 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.78% | N/A |
| EPS Growth | 25.16 | ★ 57.95 |
| EPS | 1.92 | ★ 2.46 |
| Revenue | ★ $1,190,099,000.00 | $452,477,000.00 |
| Revenue This Year | $9.90 | $10.14 |
| Revenue Next Year | N/A | $12.56 |
| P/E Ratio | ★ $24.57 | $28.46 |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $42.18 | $39.71 |
| 52 Week High | $52.39 | $73.69 |
| Indicator | OHI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 59.84 |
| Support Level | $43.94 | $55.28 |
| Resistance Level | $48.88 | $73.69 |
| Average True Range (ATR) | 1.04 | 2.50 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 48.95 | 53.04 |
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.